Navigation Links
Ultra Q - SLT-upgradeable, Nd: YAG Photodisruptor

ProductsUltra Q - SLT-upgradeable, Nd: YAG Photodisruptor
Company Ellex (formerly Laserex)
Item Ultra Q - SLT-upgradeable, Nd: YAG Photodisruptor
Features 
  • Laser Type: Q-switched Nd:YAG
  • Wavelength: 1064 nm
  • Laser safety class: Class3B
  • Energy selector: 0.3 to 10 mJ, single pulse continuously variable (<55 mJ maximum at triple pulse)
  • Pulse width: 4 ns
  • Burst mode: 1, 2 and 3 pulses per shot, selectable at 20 s separation
  • Air breakdown: <2.8mJ*
  • Mode structure: Fundamental, diffraction limited
  • Spot size: 8 m
  • Cone angle: 16 degrees
  • Posterior offset: 100 m - 350 m, continuously variable
  • Repetition rate: 2.3 Hz, single pulse*, 1.8 Hz, double pulse, 1.6 Hz, triple pulse
  • Aiming beam: Semiconductor laser diode, continuous wave twin spot, 635 nm wavelength
  • Laser delivery: Laserex slit lamp with Galilean type stereoscopic 16x microscope with converging optics
  • Magnification: Three-position, detachable, 10x, 16x, 28x
  • Safety filter: Fixed, colour-balanced
  • Table dimensions: 445 mm x 920 mm
  • Weight: 26 kg
    • Description The Laserex Ultra Q is a hospital grade Nd: YAG laser photodisruptor system that provides ophthalmologists with a precise, reliable means for performing posterior capsulotomy, iridotomy and pupillary membranectomy. The system can be used for the treatment of secondary cataracts or opacification of the capsule (posterior capsulotomy), and closed-angle glaucoma (iridotomy).
    The Ultra Q is Laserexs flagship YAG laser, with its fully integrated Nd: YAG laser photodisruptor and in-built motorised stand. The systems integrated slit lamp design continues the Laserex tradition of leading edge integrated laser products. The unique slimline design and true ergonomics provide the benefits of ease of use coupled with patient-friendly features to fit all sizes. The Ultra Q provides more patient leg room, greater height adjustment range and an outboard chinrest all in the one package.
    The Ultra Q produces a 1064 nm wavelength treatment laser from a Q-switched Nd: YAG laser cavity located in the systems laser head housing. The major feature of the Ultra Q is its improved efficiency in producing tissue disruption. The systems lower air breakdown energy means that less energy is required to generate the same amount of disruption on the target tissue. This lower level of air breakdown energy dramatically reduces the incidence of IOL pitting; and this is especially important for silicone IOLs, which have a lower damage threshold.
    The Laserex Ultra Q is available in a Total Mobile stand or Total Access stand (wheelchair-accessible) configuration. Both stands are motorised for easy table height adjustment.
    Info Ellex (formerly Laserex)
    Customer Service: (800) 824-7444
    Web site: http://us.ellex.com/

    Related medicine products :

    1. Ultrasonic Pachymeter UP-1000
    2. Ultramatic RX Master PHOROPTOR Refracting Instrument - Minus Cylinder Black
    3. Ultramatic RX Master PHOROPTOR Refracting Instrument - Plus Cylinder Black
    4. Compact Ultrasonic Phacoemulsification System
    5. Osher Ultra Fine Tying Forceps
    6. Ultrazyme Enzymatic Cleaner
    7. Ultra Thin Sheet
    8. Ultra MD40 Super Pulse CO2 Surgical Laser
    9. Ultra MD 60 Super Pulse CO2 Surgical Laser
    10. Ultra MD 80 Super Pulse CO2 Surgical Laser
    11. UltraPulse SurgiTouch CO2 Laser System
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products:
    (Date:5/21/2013)... roles two proteins, thrombospondin-1 and prosaposin, play in ... identified a five-amino acid fragment of prosaposin that ... prostate, breast and lung cancer. The findings suggest ... in a variety of cancers. , The ... Boston Children,s Hospital, Vivek Mittal, PhD, at Weill ...
    (Date:5/21/2013)... the removal of the adenoids and tonsils, is performed ... as a treatment for children with obstructive sleep apnea. ... attention and executive functioning, behavior, sleep apnea symptoms, and ... now. A study led by Susan Redline, MD, ... Cardiovascular Medicine and Associate Clinic Director of the Division ...
    (Date:5/21/2013)... Harbor, Florida (PRWEB) May 21, 2013 ... agency, announced today that they have redesigned their website ... a nude beach, pool, hot tubs, bars and dining. ... this nudist resort including sales and guest reviews, will ... island of Jamaica itself, including pages on culinary local ...
    (Date:5/21/2013)... The American Diabetes Association ( http://goo.gl/YRSF1 ... United States of America are affected with peripheral neuropathy. ... risk of developing peripheral neuropathy which unfortunately makes it ... further goes on saying that the disease usually affects ... million new cases are diagnosed every year in the ...
    (Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
    Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2
    ... Two Chinese soybean lines that grow without the primary ... have been isolated by scientists//. ,The two lines ... given away to breeders seeking to produce new varieties ... scientists at the University of Illinois at Urbana-Champaign and ...
    ... into action by mutations of the virus into a human flu ... what plan of action can we rely on to control the ... countries are teaming up next month to roll out a mock ... a pandemic. ,Australia and Singapore will be co-coordinating the ...
    ... of the out of hours health care system in England as ... ,The public accounts committee claimed that the new health care ... many key targets. ,In 2004 most GPs had opted ... PCTs took over in 90% of cases. ,The NAO ...
    ... plans for slow suffocation of millions of poultry, in ... ,According to Compassion in World Farming (CIWF) ... have been amended under emergency procedures whereby the Secretary ... a method of culling poultry in the event of ...
    ... a type 1 diabetic has been reported missing in West ... of medication// leaving her gravely ill, police have appealed for ... home in Uphall, at 2 pm on Monday. Stephanie went ... in Livingston. She is white, 5 ft 2in, of stocky ...
    ... University in Scotland found that women with high levels ... following in vitro fertilization. They found that the supplement ... after fertility treatment. ,However, the researchers said ... birth defects such as spina bifida, does not affect ...
    Cached Medicine News:Health News:Promise for Soya Allergy Sufferers 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
    (Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
    (Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
    (Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
    Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10